Pfizer Reports Phase 2 Data for Rozanolixizumab in Hidradenitis suppurativa

Pfizer today announced Phase 2 results for Rozanolixizumab in patients with Hidradenitis suppurativa. The study demonstrated that Rozanolixizumab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Hidradenitis suppurativa and support the continued development of Rozanolixizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Rozanolixizumab was consistent with previous observations, with no new safety signals identified.